Abstract

Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective

Author(s): Timko Robert J, Crooker Philip EM

Issue: Mar/Apr 2014 - Volume 18, Number 2

Page(s): 101-111

Download in electronic PDF format for $75
  • Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 1
  • Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 2
  • Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 3
  • Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 4
  • Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 5
  • Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 6
  • Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 7
  • Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 8
  • Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 9
  • Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 10
  • Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 11

Abstract

At one time, nearly all prescriptions were compounded preparations. There is an ongoing demand for compounded prescription medications because manufacturers cannot fulfill the needs of all individual patients. Compounding pharmacies are a long standing yet less frequently discussed element in the complex matrix of prescription drug manufacturing, distribution, and patient use. The drug shortage situation for many necessary and life-saving drug products is a complicating factor that has led to the numerous quality issues that currently plague large-scale compounding pharmacies. The states are the primary regulator of pharmacies, including community drug stores, large chains, and specialty pharmacies. Pharmacies making and distributing drugs in a way that is outside the bounds of traditional pharmacy compounding are of great concern to the U.S. Food and Drug Administration. The U.S. Congress has recently passed the Drug Quality and Security Act. This legislation establishes a clear boundary between traditional compounders and compounding manufacturers. It clarifies a national, uniform set of rules for compounding manufacturers while preserving the states’ primary role in traditional pharmacy regulation. It clarifies the U.S. Food and Drug Administration’s authority over the compounding of human drugs while requiring the Agency to engage and coordinate with states to ensure the safety of compounded drugs.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2014
Pg. 101-111
Jul/Aug 2016
Pg. 351
View Sample
Author(s): Allen Loyd V Jr
Mar/Apr 2015
Pg. 104-106
Author(s): Miller David G
Mar/Apr 2018
Pg. 92
Author(s): Allen Loyd V Jr
Sep/Oct 2017
Pg. 356
Author(s): Allen Loyd V Jr
Nov/Dec 2015
Pg. 453-463
Author(s): Timko Robert J
Sep/Oct 2016
Pg. 367-374
May/Jun 2004
Pg. 181-185
Sep/Oct 2020
Pg. 371-379
Jan/Feb 2017
Pg. 4
Author(s): Allen Loyd V Jr
Mar/Apr 2017
Pg. 95-102
Author(s): Yoch Doug
Jul/Aug 2020
Pg. 322-326
Sep/Oct 2017
Pg. 373-380
Author(s): Akers Michael J
Nov/Dec 2015
Pg. 487-488
Author(s): Allen Loyd V Jr
Sep/Oct 2018
Pg. 401-404
Author(s): Martin Matt
Jan/Feb 2014
Pg. 6-12
Nov/Dec 2022
Pg. 444
Author(s): Allen Loyd V Jr
Sep/Oct 2015
Pg. 389-390
Author(s): Allen Loyd V Jr
Jan/Feb 2014
Pg. 35-36
Author(s): Miller David G
Nov/Dec 2020
Pg. 451-458